EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 15c
Tweet
Share
E-mailGet Alerts EYPT Hot Sheet
Join SI Premium – FREE
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($1.09), $0.15 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $507 thousand versus the consensus estimate of $383 thousand.
For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Marchex (MCHX) Reports In-Line Q2 EPS
- Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
